# ClinicalTrials.gov record NCT00754442

> PeptideScanner retained ClinicalTrials.gov record NCT00754442 at 2026-07-30T19:40:58.915Z. Its registry update date was 2022-04-01, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00754442-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-04-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00754442-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00754442-teriparatide-v1.json
- Content SHA-256: `9951472c15b16d84e5291275066c5f3de7015f160f67eeb284f80dcc1105fdc0`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT00754442 ([`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`](#source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00754442 at 2026-07-30T19:40:58.915Z. Its registry update date was 2022-04-01, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`](#source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00754442 at 2026-07-30T19:40:58.915Z. Its registry update date was 2022-04-01, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`](#source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`](#source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836))

## Sources

<a id="source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836"></a>
- **ClinicalTrials.gov record NCT00754442 · retained source version 2022-04-01:4c0bb0f8a836a5fd0e931e1590f8838c6f602f336f707a6d445db60e5face295** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00754442) (`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00754442." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00754442-teriparatide-v1.json SHA-256: 9951472c15b16d84e5291275066c5f3de7015f160f67eeb284f80dcc1105fdc0.